These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29398430)

  • 41. Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy.
    Tada H; Kobayashi J; Kawashiri MA; Miyashita K; Nohara A; Inazu A; Nakajima K; Mabuchi H; Yamagishi M
    Lipids Health Dis; 2016 Apr; 15():66. PubMed ID: 27039080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia.
    Paquette M; Dufour R; Baass A
    J Clin Lipidol; 2017; 11(1):80-86. PubMed ID: 28391914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study.
    Ho CLB; Chowdhury EK; Breslin M; Doust J; Reid CM; Wing LMH; Nelson MR;
    J Clin Lipidol; 2019; 13(1):148-155. PubMed ID: 30293937
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.
    Brunham LR; Cermakova L; Lee T; Priecelova I; Alloul K; de Chantal M; Francis GA; Frohlich J
    Can J Cardiol; 2017 Mar; 33(3):385-392. PubMed ID: 27931859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
    Davidson M
    Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients.
    Béliard S; Millier A; Carreau V; Carrié A; Moulin P; Fredenrich A; Farnier M; Luc G; Rosenbaum D; Toumi M; Bruckert E;
    J Clin Lipidol; 2016; 10(5):1129-1136.e3. PubMed ID: 27678429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy.
    Burke JP; Simpson RJ; Paoli CJ; McPheeters JT; Gandra SR
    J Clin Lipidol; 2016; 10(6):1470-1480.e3. PubMed ID: 27919365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.
    Mabuchi H; Koizumi J; Shimizu M; Kajinami K; Miyamoto S; Ueda K; Takegoshi T
    Am J Cardiol; 1998 Dec; 82(12):1489-95. PubMed ID: 9874053
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
    Hallberg S; Banefelt J; Fox KM; Mesterton J; Johansson G; Levin LÅ; Sobocki P; Gandra SR
    Int J Clin Pract; 2016 Mar; 70(3):222-8. PubMed ID: 26799539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia.
    Paquette M; Chong M; Thériault S; Dufour R; Paré G; Baass A
    J Clin Lipidol; 2017; 11(3):725-732.e5. PubMed ID: 28456682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of cardiovascular events with the use of lipid-lowering medication in patients with familial hypercholesterolemia or severe primary hypercholesterolemia: A systematic review.
    Masson W; Corral P; Barbagelata L; Lavalle-Cobo A; Nogueira JP; Siniawski D; Ray KK
    J Clin Lipidol; 2022; 16(5):562-573. PubMed ID: 35918256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia.
    Paquette M; Bernard S; Ruel I; Blank DW; Genest J; Baass A
    J Clin Lipidol; 2019; 13(1):123-128. PubMed ID: 30318454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice.
    Catapano AL; Lautsch D; Tokgözoglu L; Ferrieres J; Horack M; Farnier M; Toth PP; Brudi P; Tomassini JE; Ambegaonkar B; Gitt AK
    Atherosclerosis; 2016 Sep; 252():1-8. PubMed ID: 27494444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
    JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Premature cardiovascular disease in young women with heterozygous familial hypercholesterolemia.
    van der Graaf A; Hutten BA; Kastelein JJ; Vissers MN
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):345-51. PubMed ID: 16716095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
    Benn M; Watts GF; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3956-64. PubMed ID: 22893714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P
    Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.